Cytokinetics Inc (CYTK) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Cytokinetics Inc (CYTK) has a cash flow conversion efficiency ratio of 0.921x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-159.84 Million) by net assets ($-173.49 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Cytokinetics Inc market capitalisation for the company's overall valuation and market capitalisation.
Cytokinetics Inc - Cash Flow Conversion Efficiency Trend (2002–2025)
This chart illustrates how Cytokinetics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Cytokinetics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cytokinetics Inc ranked by their cash flow conversion efficiency. Explore earnings quality score of Cytokinetics Inc to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Orient Sec Co Ltd
SHG:600958
|
0.133x |
|
Insulet Corporation
NASDAQ:PODD
|
0.087x |
|
Inner Mongolia Yitai Coal Co Ltd
SHG:900948
|
0.046x |
|
Rexel S.A
PA:RXL
|
0.147x |
|
Frontier Communications Parent Inc
NASDAQ:FYBR
|
0.107x |
|
Popular Inc
NASDAQ:BPOP
|
0.043x |
|
Watts Water Technologies Inc
NYSE:WTS
|
0.047x |
|
SUBARU CORP. ADR/1/2
F:FUH0
|
N/A |
Annual Cash Flow Conversion Efficiency for Cytokinetics Inc (2002–2025)
The table below shows the annual cash flow conversion efficiency of Cytokinetics Inc from 2002 to 2025. View CYTK share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-659.62 Million | $-510.01 Million | 0.773x | -73.56% |
| 2024-12-31 | $-135.37 Million | $-395.89 Million | 2.924x | +172.68% |
| 2023-12-31 | $-386.32 Million | $-414.33 Million | 1.073x | -61.36% |
| 2022-12-31 | $-107.90 Million | $-299.52 Million | 2.776x | +574.97% |
| 2021-12-31 | $243.86 Million | $-142.52 Million | -0.584x | -840.97% |
| 2020-12-31 | $113.38 Million | $8.94 Million | 0.079x | -99.05% |
| 2019-12-31 | $-10.94 Million | $-90.91 Million | 8.312x | +312.97% |
| 2018-12-31 | $25.93 Million | $-101.22 Million | -3.903x | -321.28% |
| 2017-12-31 | $109.84 Million | $-101.76 Million | -0.926x | -336.38% |
| 2016-12-31 | $94.36 Million | $36.98 Million | 0.392x | +450.52% |
| 2015-12-31 | $68.59 Million | $4.88 Million | 0.071x | +114.62% |
| 2014-12-31 | $92.06 Million | $-44.84 Million | -0.487x | -243.58% |
| 2013-12-31 | $54.44 Million | $-7.72 Million | -0.142x | +69.71% |
| 2012-12-31 | $71.44 Million | $-33.44 Million | -0.468x | +50.54% |
| 2011-12-31 | $48.18 Million | $-45.59 Million | -0.946x | -48.86% |
| 2010-12-31 | $70.52 Million | $-44.83 Million | -0.636x | -866.19% |
| 2009-12-31 | $101.43 Million | $8.42 Million | 0.083x | +106.73% |
| 2008-12-31 | $49.77 Million | $-61.33 Million | -1.232x | -3997.48% |
| 2007-12-31 | $99.92 Million | $-3.00 Million | -0.030x | +93.22% |
| 2006-12-31 | $106.31 Million | $-47.17 Million | -0.444x | +17.34% |
| 2005-12-31 | $73.56 Million | $-39.48 Million | -0.537x | -69.64% |
| 2004-12-31 | $107.56 Million | $-34.03 Million | -0.316x | -195.43% |
| 2003-12-31 | $-92.03 Million | $-30.51 Million | 0.332x | -9.93% |
| 2002-12-31 | $-60.59 Million | $-22.30 Million | 0.368x | -- |
About Cytokinetics Inc
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral… Read more